Pathological Complete Response with Intensive Hormonal Suppression Before Prostate Cancer Surgery

In patients with locally advanced prostate cancer, radical prostatectomy surgery was preceded by neoadjuvant (tumor-shrinking) treatment; adding abiraterone and prednisone to hormonal suppression with enzalutamide and leuprolide increased the rates of pathological complete response and minimal residual disease. The study was presented in April 2019 in the Journal of Clinical Oncology journal.
In this open-label, multicenter phase-II clinical trial, 75 patients were randomly assigned to two groups in a 2-to-1 ratio:
- In group 1, 50 patients received abiraterone 1.000 mg / day, enzalutamide 160 mg / day, leuprolide (leuprolide) every 12 weeks at 22.5 mg and prednisone at 5 mg / day for 24 weeks. This intensive hormonal suppression regimen was named ELAP .
- In group 2, 25 patients received enzalutamide 160 mg / day and leuprolide every 12 weeks at 22.5 mg for 24 weeks (EL group).
- Patients in both groups underwent radical prostatectomy after neoadjuvant treatment.
- The patients had prostate magnetic resonance imaging showing T3 disease (the tumor had extended beyond the prostate capsule). Lymph nodes were required to be <20 mm. The Gleason score had to be 4 + 3 = 7 or higher, and prostate-specific antigen (PSA)> 20 ng / mL or higher.
The study’s primary endpoint was the absence of any cancer cells in the surgically removed prostate tissue, known as pathological complete response , or minimal residual disease, meaning ≤5 mm of tumor remained. Most patients (% 87), according to the United States National Comprehensive Cancer Network (NCCN®) criteria, had high-risk prostate cancer.
Response Rates
- In the ELAP group, the rate of pathological complete response or minimal residual disease was % 30 (among 50 patients, 15). Pathological complete response occurred in %10 of patients in this group.
- In the EL group, the rate of pathological complete response or minimal residual disease was %16 (among % 25 patients, 4). The pathological complete response rate was % 8. These differences did not reach statistical significance (p=0.263).
- Positive surgical margin and positive lymph node rates were similar between the two groups.
- Molecular profiling of tumor samples showed that tumors positive for ERG and with PTEN loss had greater residual (remaining tumor) volume, and these two features were considered to be associated with less favorable outcomes.
Adverse Effects
- Treatment was well tolerated in both groups.
- Treatment-related adverse effects were similar between the groups, except for the rates of any-grade and grade 3. hypertension, ALT, and AST in the ELAP group.
- No treatment-related grade 4. adverse effects (requiring hospitalization) were observed.
In conclusion, this small clinical trial appears to have achieved the best results to date with intensive hormonal suppression in neoadjuvant (preoperative tumor-shrinking) treatment for prostate cancer. However, longer follow-up is needed to assess the effects of the ELAP regimen on recurrence rates and overall survival.
Sources
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
J Clin Oncol. 10 April 2019.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.